Table 1.
Association between ZNF276 expression and clinicopathologic features of patients with breast cancer (n = 118).
| Characteristics | ZNF276 expression | Total | P value | |
|---|---|---|---|---|
| Low (n %) | High (n %) | |||
| Age (years) | 0.032* | |||
| ≤60 | 45 (57.7%) | 33 (42.3%) | 78 | |
| 60 | 14 (35%) | 26 (65%) | 40 | |
| WHO grade | 0.046* | |||
| I (I–II) | 0 | 4 (100%) | 4 | |
| II | 32 (46.4%) | 37 (53.6%) | 69 | |
| III (II–III) | 27 (60%) | 18 (40%) | 45 | |
| Tumor size (cm) | 0.579 | |||
| ≤3 | 34 (52.3%) | 31 (47.7%) | 65 | |
| >3 | 25 (47.2%) | 28 (52.8%) | 53 | |
| TNM grade | ||||
| T | 0.030* | |||
| T1 | 13 (81.3%) | 3 (18.7%) | 16 | |
| T2 | 36 (42.4%) | 49 (57.6%) | 85 | |
| T3 | 8 (61.5%) | 5 (38.5%) | 13 | |
| T4 | 2 (50%) | 2 (50%) | 4 | |
| N | 0.370 | |||
| N0 | 19 (43.2%) | 25 (56.8%) | 44 | |
| N1 (pN1) | 20 (51.3%) | 19 (48.7%) | 39 | |
| N2 (pN2) | 9 (47.4%) | 10 (52.6%) | 19 | |
| N3 (pN3) | 11 (68.8%) | 5 (31.2%) | 16 | |
| Clinical stage | 0.050* | |||
| 1 | 8 (80%) | 2 (20%) | 10 | |
| 2 | 29 (42%) | 40 (58%) | 69 | |
| 3 | 22 (56.4%) | 17 (43.6%) | 39 | |
| ER | 0.038* | |||
| + | 8 (40%) | 12 (60%) | 20 | |
| − | 36 (66.7%) | 18 (33.3%) | 54 | |
| PR | 0.089 | |||
| + | 10 (41.7%) | 14 (58.3%) | 24 | |
| − | 26 (63.4%) | 15 (36.6%) | 41 | |
| Her2 | 0.863 | |||
| + | 8 (61.5%) | 5 (38.5%) | 13 | |
| − | 33 (58.9%) | 23 (41.1%) | 56 | |
| Ki67 | 0.912 | |||
| Low (≤50%) | 34 (54%) | 29 (46%) | 63 | |
| High (>50%) | 1 (50%) | 1 (50%) | 2 | |
ER oestrogen receptors, PR progesterone receptors, HER2 human epidermal growth factor receptor-2, *P < 0.05.